Back to results
US 2025/0199015 A1Published application
Cyclin-dependent kinase 2 inhibitors for medical treatment
AssigneeIncyclix Bio, LLC
InventorsJay Copeland Strum, John E. Bisi, Alec Gibson Trub
Life of this patent
Estimating the term…
Abstract
Use of a pyrimidine-based selective cyclin-dependent kinase 2 (CDK2) of structure: or a pharmaceutically acceptable salt thereof or morphic form described herein for the treatment of disorders characterized by aberrant cellular division having amplified cyclin E activation and/or expression or aberrant cellular division disorders, CDK4/6 resistance, and/or endocrine therapy resistance, including but not limited to the treatment of tumors and cancers.
Claims16
A method for treating a human patient with an abnormal cellular proliferation, comprising:
- (i) obtaining a sample from the human patient;
- (ii) detecting whether cyclin E1 (CCNE1) and/or cyclin E2 (CCNE2) are overexpressed and/or amplified in the sample compared with a control sample;
- and
- (iii) if CCNE1 and/or CCNE2 are overexpressed and/or amplified, administering to the human patient an effective amount of a compound of structure:
- or a pharmaceutically acceptable salt thereof.
2 more elements
Dependencies are inferred from the claim text.